Seres Therapeutics, Inc. (MCRB)
| Previous close | 6.09 |
| Open | 6.10 |
| Bid | 5.78 x 900 |
| Ask | 6.40 x 800 |
| Day's range | 5.92 - 6.17 |
| 52-week range | 2.50 - 9.49 |
| Volume | |
| Avg. volume | 880,983 |
| Market cap | 730.109M |
| Beta (5Y monthly) | 2.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
CAMBRIDGE, Mass., March 09, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023 at 8:40 a.m. ET.
- Business Wire
Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
CAMBRIDGE, Mass., March 07, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2022 financial results and provided business updates.
- Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 03, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on March 1, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 15,500 shares of its common stock to three new employees, consisting of stock options to purchase an aggregate of 9,250 shares of common stock and restricted stock units ("RSUs"), covering an
